Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 7

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 7
---
, shares represented by proxy will be voted for the election of a substitute nominee designated by the current Board, unless otherwise marked on the card. The nominees have each agreed to serve as a director if elected. We have no reason to believe that any of the nominees will be unable to serve if elected. Certain information about each of the nominees is furnished below, including their business experience, public company director positions held currently or at any time during the last five years and the experience, qualifications, attributes or skills that caused the Nominating and Corporate Governance Committee and the Board to determine that the nominees should continue to serve as directors. Our directors have a diverse set of skills and experience on the board, including: • all of our directors have life sciences experience, including with respect to gene therapy; • all of our directors have deep public company or executive leadership experience; • five of our directors have experience in medicine, science, academia or research; • three of our directors have finance, accounting or IT experience; • two of our directors have regulatory, public policy or legal experience; • three of our directors have commercial experience and; • four of our directors have international experience.

| Name                        |     | Age |     | Positions and Offices Held                      
 with Company                                    |     | Director Since |
| Allan M. Fox                |     |  77 |     | Director                                        |     |           2009 |
| Alexandra Glucksmann, Ph.D. |     |  66 |     | Director                                        |     |           2018 |
| Curran Simpson              |     |  63 |     | Director, President and Chief Executive Officer |     |           2024 |
| Jennifer Zachary            |     |  47 |     | Director                                        |     |           2022 |

Allan M. Fox has been a Director since February 2009 and served as Chairman from June 2020 until June 2024. Mr. Fox is the founding partner of FOXKISER, a firm committed to the strategic development of transformative innovations from biomedical research, which was formed in September 1986. Mr. Fox specializes in identifying business opportunities and improving competitive market positions. Through FOXKISER, he has participated in the formation and development of numerous ventures in the public and private sectors, including the founding of REGENXBIO and Dimension Therapeutics, Inc. Before forming FOXKISER, Mr. Fox co-led the establishment of the Washington office of the law firm of Kaye Scholer. While